Zhuo Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhuo Chen has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Qianbin Li
Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, Hunan, China; Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Changsha 410013, Hunan, China; Hunan Key Laboratory of Organ Fibrosis, Changsha 410013, Hunan, China
15 shared publications Gaoyun Hu
Department of Medicinal Chemistry , Xiangya School of Pharmaceutical Sciences, Central South University , Changsha , Hunan , China
9 shared publicationsQianbin Li
8 shared publicationsLei Zhang
6 shared publicationsLiqing Hu
Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Pharmaceutical Sciences
6 shared publicationsQingsong Chen
5 shared publications
Latest Publications
- 11 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (10) , 12205-12222
Identification of an Hsp110/HDAC6 Dual-Target Inhibitor for the Effective Treatment of Pulmonary Arterial Hypertension via Synergistic Blockade of Vascular Remodeling
Recent studies suggested that disrupting the Hsp110-STAT3 interaction is a promising strategy for treating pulmonary arterial hypertension (PAH). However, the restricted reduction in p-STAT3 required to prevent vascular remodeling limits Hsp110-STAT3 PPI inhibitor development. Our preliminary studies revealed that HDAC6 activation in HPAECs contributes to p-STAT3 upregulation. Subsequently, a series of Hsp110/HDAC6 dual-target inhibitors were rationally designed and synthesized. Structure-activity relationship studies identified 15n as a potent dual-target inhibitor, effectively interrupting the Hsp110-STAT3 interaction and suppressing HDAC6 activity. In vitro, 15n exhibited a synergistic effect in suppressing the STAT3 signaling pathway by concurrently targeting Hsp110 and HDAC6, thereby inhibiting the abnormal proliferation and migration of the HPAECs. In vivo, compared with combination therapy, 15n demonstrated enhanced suppressive effects on vascular remodeling through synchronous regulation of dual targets. In summary, the present study provides novel research insights into developing novel PAH drugs based on antivascular remodeling strategies and offers a promising lead compound.
- 11 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (10) , 12205-12222
Identification of an Hsp110/HDAC6 Dual-Target Inhibitor for the Effective Treatment of Pulmonary Arterial Hypertension via Synergistic Blockade of Vascular Remodeling
Recent studies suggested that disrupting the Hsp110-STAT3 interaction is a promising strategy for treating pulmonary arterial hypertension (PAH). However, the restricted reduction in p-STAT3 required to prevent vascular remodeling limits Hsp110-STAT3 PPI inhibitor development. Our preliminary studies revealed that HDAC6 activation in HPAECs contributes to p-STAT3 upregulation. Subsequently, a series of Hsp110/HDAC6 dual-target inhibitors were rationally designed and synthesized. Structure-activity relationship studies identified 15n as a potent dual-target inhibitor, effectively interrupting the Hsp110-STAT3 interaction and suppressing HDAC6 activity. In vitro, 15n exhibited a synergistic effect in suppressing the STAT3 signaling pathway by concurrently targeting Hsp110 and HDAC6, thereby inhibiting the abnormal proliferation and migration of the HPAECs. In vivo, compared with combination therapy, 15n demonstrated enhanced suppressive effects on vascular remodeling through synchronous regulation of dual targets. In summary, the present study provides novel research insights into developing novel PAH drugs based on antivascular remodeling strategies and offers a promising lead compound.
- 22 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 11448-11470
Identification of Nitric Oxide-Donating Lenumlostat Derivatives with Dual Activities of Extracellular Matrix Dysregulation Inhibition and Pulmonary Vasodilation for the Treatment of Pulmonary Arterial Hypertension
Based on two key pathological features of pulmonary arterial hypertension (PAH), elevated pulmonary artery pressure and vascular remodeling, two new series of nitric oxide (NO) donating lenumlostat derivatives were designed, synthesized, and biologically evaluated. The results indicated that compound LNO 9 exhibited LOXL2 inhibitory activity comparable to lenumlostat, remarkably suppressing hypoxia-induced collagen oxidation and aberrant collagen cross-linking. Furthermore, LNO 9 effectively released NO and increased 3',5'-cyclic guanosine monophosphate in HPASMCs, thereby exerting a potent vasodilation. In both hypoxia- and MCT-induced rat models of PAH, LNO 9 significantly improved right ventricular hypertrophy and pulmonary arterial medial wall thickness. Meanwhile, LNO 9 demonstrated superior efficacy in reducing right ventricular systolic pressure compared to lenumlostat. In short, the present study has demonstrated unequivocally that a therapeutic approach for PAH that combines NO donors for vasodilation with extracellular matrix inhibitors to suppress vascular remodeling represents a promising treatment.
- 22 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 11448-11470
Identification of Nitric Oxide-Donating Lenumlostat Derivatives with Dual Activities of Extracellular Matrix Dysregulation Inhibition and Pulmonary Vasodilation for the Treatment of Pulmonary Arterial Hypertension
Based on two key pathological features of pulmonary arterial hypertension (PAH), elevated pulmonary artery pressure and vascular remodeling, two new series of nitric oxide (NO) donating lenumlostat derivatives were designed, synthesized, and biologically evaluated. The results indicated that compound LNO 9 exhibited LOXL2 inhibitory activity comparable to lenumlostat, remarkably suppressing hypoxia-induced collagen oxidation and aberrant collagen cross-linking. Furthermore, LNO 9 effectively released NO and increased 3',5'-cyclic guanosine monophosphate in HPASMCs, thereby exerting a potent vasodilation. In both hypoxia- and MCT-induced rat models of PAH, LNO 9 significantly improved right ventricular hypertrophy and pulmonary arterial medial wall thickness. Meanwhile, LNO 9 demonstrated superior efficacy in reducing right ventricular systolic pressure compared to lenumlostat. In short, the present study has demonstrated unequivocally that a therapeutic approach for PAH that combines NO donors for vasodilation with extracellular matrix inhibitors to suppress vascular remodeling represents a promising treatment.
- 21 March 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 249, 117916
Discovery and research progress of CDK8 inhibitors
- 21 March 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 249, 117916
Discovery and research progress of CDK8 inhibitors
- Open Access
- 1 March 2026
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 76 (1) , 1-13
Pan-Cdk inhibitor ZK304709 suppresses Cdc20 expression and potentiates the anticancer activity of apcin in HeLa cervical cancer cells
Cell division cycle 20 homologue (Cdc20), a key regulator of the anaphase-promoting complex/cyclosome (APC/C), is frequently overexpressed in human cancers and represents a promising therapeutic target. However, monotherapy targeting Cdc20 has shown limited efficacy, partly due to compensatory activation of cyclin-dependent kinase 1 (Cdk1). In this study, we investigated the combinatorial potential of the pan-Cdk inhibitor ZK304709 with the Cdc20 inhibitor apcin in HeLa cervical cancer cells. Transcriptomic analysis revealed that both CDC20 and CDK1 are upregulated in cervical cancer tissues. Mechanistically, apcin treatment induced cyclin B1 accumulation and enhanced Cdk1 phosphorylation at Thr161, suggesting feedback activation. In contrast, ZK304709 reduced p -Cdk1(T161) levels and suppressed Cdc20 expression at both protein and mRNA levels. Functionally, the combination of apcin and ZK304709 synergistically inhibited cell proliferation and induced G2/M phase arrest in HeLa cells. These findings demonstrate that dual inhibition of Cdk1 and Cdc20 disrupts compensatory signalling pathways and enhances antitumour efficacy in HeLa cells, providing a rational strategy for combination therapy in cervical cancer.
- 1 March 2026
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 76 (1) , 1-13
Open AccessPan-Cdk inhibitor ZK304709 suppresses Cdc20 expression and potentiates the anticancer activity of apcin in HeLa cervical cancer cells
Cell division cycle 20 homologue (Cdc20), a key regulator of the anaphase-promoting complex/cyclosome (APC/C), is frequently overexpressed in human cancers and represents a promising therapeutic target. However, monotherapy targeting Cdc20 has shown limited efficacy, partly due to compensatory activation of cyclin-dependent kinase 1 (Cdk1). In this study, we investigated the combinatorial potential of the pan-Cdk inhibitor ZK304709 with the Cdc20 inhibitor apcin in HeLa cervical cancer cells. Transcriptomic analysis revealed that both CDC20 and CDK1 are upregulated in cervical cancer tissues. Mechanistically, apcin treatment induced cyclin B1 accumulation and enhanced Cdk1 phosphorylation at Thr161, suggesting feedback activation. In contrast, ZK304709 reduced p -Cdk1(T161) levels and suppressed Cdc20 expression at both protein and mRNA levels. Functionally, the combination of apcin and ZK304709 synergistically inhibited cell proliferation and induced G2/M phase arrest in HeLa cells. These findings demonstrate that dual inhibition of Cdk1 and Cdc20 disrupts compensatory signalling pathways and enhances antitumour efficacy in HeLa cells, providing a rational strategy for combination therapy in cervical cancer.
- 13 December 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (24) , 26547-26573
Design and Optimization of LOXL2 and sGC Dual-Target Regulators Targeting Extracellular Matrix Dysregulation and Vasodilation for the Treatment of Pulmonary Arterial Hypertension
Current vasodilator therapies for pulmonary arterial hypertension (PAH) improve outcomes but remain limited in halting disease progression. Emerging evidence suggests that dual-acting agents targeting both vasodilation and vascular remodeling demonstrate superior efficacy. Leveraging the distinct roles of LOXL2 in vascular remodeling and sGC in vasodilation, we designed and synthesized a series of 4-(aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine derivatives as dual LOXL2/sGC modulators via fragment fusion strategy. In vitro, compound 11k emerged as the most potent candidate, significantly suppressing pathological collagen cross-linking and malignant phenotypes while promoting vasodilation. In a hypoxia-induced PAH rat model, its esterified derivative 9k markedly alleviated vascular remodeling and reduced pulmonary artery pressure, showing efficacy comparable to the combination of riociguat and PAT-1251. Consequently, this study proposes a novel strategy for the development of bifunctional PAH drugs, with a focus on extracellular matrix dysfunction and vasoconstriction, and has identified a promising lead compound.
- 13 December 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (24) , 26547-26573
Design and Optimization of LOXL2 and sGC Dual-Target Regulators Targeting Extracellular Matrix Dysregulation and Vasodilation for the Treatment of Pulmonary Arterial Hypertension
Current vasodilator therapies for pulmonary arterial hypertension (PAH) improve outcomes but remain limited in halting disease progression. Emerging evidence suggests that dual-acting agents targeting both vasodilation and vascular remodeling demonstrate superior efficacy. Leveraging the distinct roles of LOXL2 in vascular remodeling and sGC in vasodilation, we designed and synthesized a series of 4-(aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine derivatives as dual LOXL2/sGC modulators via fragment fusion strategy. In vitro, compound 11k emerged as the most potent candidate, significantly suppressing pathological collagen cross-linking and malignant phenotypes while promoting vasodilation. In a hypoxia-induced PAH rat model, its esterified derivative 9k markedly alleviated vascular remodeling and reduced pulmonary artery pressure, showing efficacy comparable to the combination of riociguat and PAT-1251. Consequently, this study proposes a novel strategy for the development of bifunctional PAH drugs, with a focus on extracellular matrix dysfunction and vasoconstriction, and has identified a promising lead compound.
- 17 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 22428-22454
Discovery of Cdc20/Hsp90 Dual-Target Inhibitors with Potent Antitumor Activity for Therapy of Acquired Resistant Melanoma
Cell division cycle 20 homologue (Cdc20) is a cancer-promoting protein that is expressed at higher levels in tumor tissues than in neighboring tissues, and the degradation of Cdc20 is considered to be an effective strategy to inhibit tumor growth. Here, we designed Cdc20/Hsp90 dual-target inhibitors, hoping to synergistically exert antitumor effects. The preferred compound 2b exerted an extensive antitumor spectrum and lower toxicity, which closely bound to Cdc20 and Hsp90, respectively. Additionally, compound 2b exerted potent antitumor activity through reducing p53-mediated Cdc20, upregulating Bim, downregulating Cyclin B1 expression, and disturbing B-Raf and AKT pathways via destroying Hsp90 chaperone function. Furthermore, compound 2b inhibited parental melanoma growth, comparable to the marketed agent Vemurafenib and superior to the combination of Apcin and BIIB021. Interestingly, compound 2b overcame Vemurafenib-induced resistant melanoma, superior to parental melanoma, indicating that compound 2b is a promising Cdc20/Hsp90 dual-target inhibitor for therapy of acquired resistance of malignant melanoma.
- 17 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 22428-22454
Discovery of Cdc20/Hsp90 Dual-Target Inhibitors with Potent Antitumor Activity for Therapy of Acquired Resistant Melanoma
Cell division cycle 20 homologue (Cdc20) is a cancer-promoting protein that is expressed at higher levels in tumor tissues than in neighboring tissues, and the degradation of Cdc20 is considered to be an effective strategy to inhibit tumor growth. Here, we designed Cdc20/Hsp90 dual-target inhibitors, hoping to synergistically exert antitumor effects. The preferred compound 2b exerted an extensive antitumor spectrum and lower toxicity, which closely bound to Cdc20 and Hsp90, respectively. Additionally, compound 2b exerted potent antitumor activity through reducing p53-mediated Cdc20, upregulating Bim, downregulating Cyclin B1 expression, and disturbing B-Raf and AKT pathways via destroying Hsp90 chaperone function. Furthermore, compound 2b inhibited parental melanoma growth, comparable to the marketed agent Vemurafenib and superior to the combination of Apcin and BIIB021. Interestingly, compound 2b overcame Vemurafenib-induced resistant melanoma, superior to parental melanoma, indicating that compound 2b is a promising Cdc20/Hsp90 dual-target inhibitor for therapy of acquired resistance of malignant melanoma.
- 9 October 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 421, 111771
Fragment-based discovery, dynamics simulation and pharmacological study of 2-amino-pyrimidine derivative as HIPK2 inhibitor
- 9 October 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 421, 111771
Fragment-based discovery, dynamics simulation and pharmacological study of 2-amino-pyrimidine derivative as HIPK2 inhibitor
- 23 September 2025
- Published by Elsevier in Drug Discovery Today
- Vol. 30 (11) , 104480
Rational discovery of molecular glue degraders based on block chemistry
- 23 September 2025
- Published by Elsevier in Drug Discovery Today
- Vol. 30 (11) , 104480
Rational discovery of molecular glue degraders based on block chemistry
- 4 March 2025
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (3) , e2400796
Discovery of a novel 2,4‐thiazolidinedione derivative as dual inhibitor of β‐catenin/TCF4 interaction and tubulin polymerization in colon cancer cells
Hyperactivation of the Wnt/β‐catenin signaling pathway has been widely recognized as a pathogenic mechanism for colorectal cancer (CRC). Based on a previously reported lead compound, iCRT14, a series of 2,4‐thiazolidinedione derivatives were designed, synthesized, and evaluated in vitro for their antiproliferative activity against colon cancer cells. Compound 15k exhibited the most potent activity against the HCT116 and SW480 cell lines. Compound 15k inhibited Wnt/β‐catenin signaling by disrupting the protein–protein interactions between β‐catenin and TCF4. Compound 15k simultaneously inhibited tubulin polymerization, disorganized the microtubule network, and arrested the cell cycle at the G2/M phase, offering an additional mechanism of action and 15k induced cell apoptosis by activating caspase‐3 and poly(ADP‐ribose) polymerase. Additionally, compound 15k inhibited cell migration without affecting the levels of β‐catenin protein. These results offer guidance for developing the current series as potential new anticancer therapeutics.
- 4 March 2025
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (3) , e2400796
Discovery of a novel 2,4‐thiazolidinedione derivative as dual inhibitor of β‐catenin/TCF4 interaction and tubulin polymerization in colon cancer cells
Hyperactivation of the Wnt/β‐catenin signaling pathway has been widely recognized as a pathogenic mechanism for colorectal cancer (CRC). Based on a previously reported lead compound, iCRT14, a series of 2,4‐thiazolidinedione derivatives were designed, synthesized, and evaluated in vitro for their antiproliferative activity against colon cancer cells. Compound 15k exhibited the most potent activity against the HCT116 and SW480 cell lines. Compound 15k inhibited Wnt/β‐catenin signaling by disrupting the protein–protein interactions between β‐catenin and TCF4. Compound 15k simultaneously inhibited tubulin polymerization, disorganized the microtubule network, and arrested the cell cycle at the G2/M phase, offering an additional mechanism of action and 15k induced cell apoptosis by activating caspase‐3 and poly(ADP‐ribose) polymerase. Additionally, compound 15k inhibited cell migration without affecting the levels of β‐catenin protein. These results offer guidance for developing the current series as potential new anticancer therapeutics.